**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam 0.5 mg/ml oral suspension for cats
meloxicam

## 2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 0.5 mg/ml

## 3. PHARMACEUTICAL FORM

Oral suspension

## 4. PACKAGE SIZE

3 ml
5 ml
10 ml
15 ml

## 5. TARGET SPECIES

Cats.

## 6. INDICATION(S)

## 7. METHOD AND ROUTE OF ADMINISTRATION

Shake well before use.
Oral use.
Read the package leaflet before use.

## 8. WITHDRAWAL PERIOD(S)

## 9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

## 10. EXPIRY DATE

EXP {month/year}
3 ml: Once opened use within 14 days.
5 ml: Once opened use within 14 days.
10 ml: Once opened use within 6 months.
15 ml: Once opened use within 6 months.
Once opened used by….

## 11. SPECIAL STORAGE CONDITIONS

## 12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

## 13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

## 14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

## 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

## 16. MARKETING AUTHORISATION NUMBER

Vm 08749/5017

## 17. MANUFACTURER'S BATCH NUMBER

BN{number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Bottle**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam 0.5 mg/ml oral suspension for cats
meloxicam

## 2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Meloxicam 0.5 mg/ml

## 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

3 ml
5 ml
10 ml
15 ml

## 4. ROUTE OF ADMINISTRATION

Oral use

## 5. WITHDRAWAL PERIOD(S)

## 6. BATCH NUMBER

BN {number}

## 7. EXPIRY DATE

EXP {month/year}

## 8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

# PACKAGE LEAFLET:
# Rheumocam 0.5 mg/ml oral suspension for cats

## 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:
Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

## 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam 0.5 mg/ml oral suspension for cats.
meloxicam

## 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

One ml contains:

Active substance
Meloxicam 0.5 mg.

Excipient
Sodium benzoate 1.5 mg.

Smooth light yellow suspension.

## 4. INDICATION(S)

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.

## 5. CONTRAINDICATIONS

Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.

## 6. ADVERSE REACTIONS

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. Gastrointestinal ulceration and elevated liver enzymes were reported in very rare cases.

These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Cats.

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Oral use.

Post-operative pain and inflammation following surgical procedures:
After initial treatment with Rheumocam 5 mg/ml solution for injection for cats, continue treatment 24 hours later with Rheumocam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to 4 days.

Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and inflammation persist.

Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.

A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

Route and method of administration
To be administered orally either mixed with food or directly into the mouth.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the dose of 0.05 mg meloxicam/kg bodyweight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required.
For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4 times the
maintenance volume will be required.

## 9. ADVICE ON CORRECT ADMINISTRATION

Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.
Please carefully follow the instructions of the veterinarian.
Avoid introduction of contamination during use.

## 10. WITHDRAWAL PERIOD(S)

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening of the container:

| | |
|---|---|
| 3 ml and 5 ml bottles: | 14 days |
| 10 ml and 15 ml bottles: | 6 months. |

## 12. SPECIAL WARNING(S)

Special precautions for use in animals:
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy should be considered.

Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. See section "Contraindications".

Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.
In case of overdose, adverse reactions, as listed in section "Adverse reactions", are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.

Incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

## 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

## 15. OTHER INFORMATION

Pack size: 1 x 3 ml, 1 x 5 ml 1 x 10 ml or 1 x 15 ml bottle with a measuring syringe.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**United Kingdom**
Chanelle Vet UK Ltd
1 High Street
Hungerford
Berkshire
RG17 0DN – UK
Tel: + 44 1488 680664

**United Kingdom (Northern Ireland)**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
IE - Ireland
Tel: + 353 91 841788

Approved 22 April 2022